Trial Summary
What is the purpose of this trial?
This is a prospective, non-randomized, interventional, dual site, before-after clinical trial to determine feasibility and safety of a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF) for the treatment of knee Post Traumatic Osteoarthritis (PTOA).
Research Team
Claude T Moorman, MD
Principal Investigator
Wake Forest University Health Sciences
Eligibility Criteria
This trial is for adults aged 18-45 who've had significant knee trauma or surgery between 1 and 20 years ago, leading to Post-Trauma Osteoarthritis (PTOA). They should have ongoing knee pain despite trying at least two treatments like medication or physical therapy. Participants need a BMI under 35, speak English, and be able to attend follow-up visits. Pregnant women, tobacco users, those with recent knee injections or certain medical conditions are excluded.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Adipose Derived (AD) Stromal Vascular Fraction (SVF) (Cell Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Dr. L. Ebony Boulware
Wake Forest University Health Sciences
Chief Medical Officer since 2022
MD from Duke University School of Medicine, MPH from Johns Hopkins Bloomberg School of Public Health
Dr. Julie Ann Freischlag
Wake Forest University Health Sciences
Chief Executive Officer since 2020
BS from University of Illinois, MD from Rush University